N C Gutierrez
Overview
Explore the profile of N C Gutierrez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
1108
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Medina-Herrera A, Vazquez I, Cuenca I, Rosa-Rosa J, Ariceta B, Jimenez C, et al.
Blood Cancer J
. 2024 Apr;
14(1):74.
PMID: 38684670
Smoldering multiple myeloma (SMM) precedes multiple myeloma (MM). The risk of progression of SMM patients is not uniform, thus different progression-risk models have been developed, although they are mainly based...
2.
Arana P, Paiva B, Cedena M, Puig N, Cordon L, Vidriales M, et al.
Leukemia
. 2017 Nov;
32(4):971-978.
PMID: 29099494
Persistence of minimal residual disease (MRD) after treatment for myeloma predicts inferior outcomes, but within MRD-positive patients there is great heterogeneity with both early and very late relapses. Among different...
3.
Jimenez C, Alonso-Alvarez S, Alcoceba M, Ordonez G, Garcia-Alvarez M, Prieto-Conde M, et al.
Blood Cancer J
. 2017 Aug;
7(8):e591.
PMID: 28841204
Transformation of Waldenström's macroglobulinemia (WM) to diffuse large B-cell lymphoma (DLBCL) occurs in up to 10% of patients and is associated with an adverse outcome. Here we performed the first...
4.
Chillon M, Jimenez C, Garcia-Sanz R, Alcoceba M, Prieto I, Garcia-Alvarez M, et al.
Ann Hematol
. 2017 Aug;
96(10):1699-1705.
PMID: 28770277
Chromosome 1q gains and 13q deletions are common cytogenetic aberrations in multiple myeloma (MM) that confer a poor prognosis. There are several techniques for the targeted study of these alterations,...
5.
Jovanovic J, Chillon M, Vincent-Fabert C, Dillon R, Voisset E, Gutierrez N, et al.
Leukemia
. 2016 Nov;
31(3):747-751.
PMID: 27872498
No abstract available.
6.
Paiva B, Puig N, Cedena M, de Jong B, Ruiz Y, Rapado I, et al.
Leukemia
. 2016 Aug;
31(2):382-392.
PMID: 27479184
The notion that plasma cells (PCs) are terminally differentiated has prevented intensive research in multiple myeloma (MM) about their phenotypic plasticity and differentiation. Here, we demonstrated in healthy individuals (n=20)...
7.
Gonzalez-Calle V, Davila J, Escalante F, de Coca A, Aguilera C, Lopez R, et al.
Leukemia
. 2016 May;
30(10):2026-2031.
PMID: 27133826
The diagnosis of smoldering multiple myeloma (SMM) includes patients with a heterogeneous risk of progression to active multiple myeloma (MM): some patients will never progress, whereas others will have a...
8.
Martinez-Moreno M, Leiva M, Aguilera-Montilla N, Sevilla-Movilla S, Isern de Val S, Arellano-Sanchez N, et al.
Leukemia
. 2015 Dec;
30(4):861-72.
PMID: 26658839
Multiple myeloma (MM) and chronic lymphocytic leukemia (CLL) cells must attach to the bone marrow (BM) microvasculature before lodging in the BM microenvironment. Using intravital microscopy (IVM) of the BM...
9.
Puig N, Conde I, Jimenez C, Sarasquete M, Balanzategui A, Alcoceba M, et al.
Leukemia
. 2015 Jan;
29(6):1435-7.
PMID: 25567133
No abstract available.
10.
Paino T, Paiva B, Sayagues J, Mota I, Carvalheiro T, Corchete L, et al.
Leukemia
. 2014 Nov;
29(5):1186-94.
PMID: 25388955
Knowledge about clonal diversity and selection is critical to understand multiple myeloma (MM) pathogenesis, chemoresistance and progression. If targeted therapy becomes reality, identification and monitoring of intraclonal plasma cell (PC)...